Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
September, 2026
September 2026
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
Céline Chapelle Shares Clinical Predictors From the API-CAT Trial
Jan 25, 2026, 15:57

Céline Chapelle Shares Clinical Predictors From the API-CAT Trial

Céline Chapelle, Biostatistician at CHU Saint-Étienne, shared on LinkedIn:

“Very happy to share our latest publication in Lancet Haematology.

“Predictors of clinically relevant bleeding during extended anticoagulation for cancer-associated venous thromboembolism (API-CAT): a post-hoc analysis of a randomised, non-inferiority trial”

In this post-hoc analysis of the API-CAT study, including patients with cancer-associated thromosis (CAT) receiving extended anticoagulant with apixaban: – Four clinical predictors were significantly associated with an increased risk of clinically relevant bleeding: anaemia and/or thrombocytopenia, age ≥75, pulmonary embolism as the index event, and male sex.

Three of them were also significant predictors of major bleeding.

Many thanks to all co-authors and collaborators for this excellent teamwork.”

Read the full article here.

Article: Predictors of clinically relevant bleeding during extended anticoagulation for cancer-associated venous thromboembolism (API-CAT): a post-hoc analysis of a randomised, non-inferiority trial

Authors: Isabelle Mahé, Céline Chapellee, Philippe Girard, Marc Carrier, Luis Jara Palomares, Charles-Marc Samama, Hélène Helfer, Prof Grigoris Gerotziafas, Silvy Laporte, Eric Vicaut, Patrick Mismetti

Céline Chapelle Shares Clinical Predictors From the API-CAT Trial

Stay updated on all scientific advances with Hemostasis Today.

Anticoagulation API-CAT Apixaban Bleeding Risk cancer CAT Celine Chapelle Health Hematology Hemostasis Hemostasis News Hemostasis Today Isabelle Mahé Lancet Haematology Medical News Medicine OncoDaily Patrick Mismetti thrombosis venous thromboembolism VTE
NewsFeed